QOL Medical, LCC: Our Beliefs and Business Model

QOL Medical, LLC is a specialty pharmaceutical company with three approved, marketed products focused on pediatric gastroenterology and rare orphan diseases. QOL seeks to acquire or invest in approved and late-stage development prescription pharmaceutical products that offer genuine clinical value for niche patient populations.

  • Our specialty is in managing unique products to ensure optimal access for appropriate patients in need.
  • We believe niche specialty patient and clinician populations are often better served with less overt emphasis on traditional sales force reach and frequency.
  • Instead, we believe that best clinical practice with these products is often defined by the clinical evidence and codified via national treatment guidelines and/or better patient identification.
  • We believe that networks of like-minded clinicians striving for best clinical outcomes for their patients appreciate strategic pharmaceutical partners that facilitate utilization of their products in concordance with treatment pathways, and not contrary to them.
  • We believe that facilitating patient identification and emphasizing patient access to treatment are the keys to optimal use.

The management team has a successful track record of acquiring under-promoted specialty pharmaceutical products and expanding sales through appropriate patient identification and diagnosis. Based on its operating strategy of acquiring approved specialty and rare disease products (avoiding the high costs of new product research and development), using efficient marketing and distribution, and employing a virtual pharmaceutical company business model (i.e., reliance on outsourcing many tasks to highly efficient third-party service providers), the management team remains focused on expanding patient access to unique products for unmet medical needs.

Important Safety Information

For a complete discussion of indications, usage, contraindications, warnings, precautions, adverse reactions, and overdosage, please see full prescribing information attached. Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, or glycerin (glycerol). Sucraid may contain papain which can cause allergic reactions in some patients. Adverse experiences with Sucraid in clinical trials were generally minor and were frequently associated with underlying disease. In clinical studies of up to 54 months duration, physicians treated a total of 52 patients with Sucraid. The adverse experiences and respective number of patients reporting each event were as follows: abdominal pain(4), vomiting(3), nausea(2), diarrhea(2), constipation(2), insomnia(1), headache(1), nervousness(1), and dehydration(1). Note: diarrhea and abdominal pain can be a part of the clinical presentation of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency. The effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency. In one clinical trial, one patient, a four year old boy who was being treated for asthma, experienced severe wheezing necessitating admission into the ICU. While reported reactions are extremely rare, care should be taken when administering initial doses of Sucraid to observe any signs of acute hypersensitivity reaction. Care should be taken to administer initial doses of Sucraid near a facility where acute hypersensitivity reactions can be adequately treated.1